Product image of Mannitol Baxter (Mannitol) supplied by GNH India

Mannitol Baxter

Active Ingredient:
Mannitol
Origin:
EU

Mannitol Baxter (Mannitol)

Mannitol, the active ingredient in Mannitol Baxter, is an osmotic diuretic presented as an injectable solution for intravenous use. It is employed to lower elevated intracranial and intraocular pressures and to promote diuresis in acute renal failure patients in clinical settings and critical care environments.

GNH India supplies Mannitol Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, clinics and pharmacies worldwide, and ensures the product meets EU pharmacopeia standards and is available in ready‑to‑use vials.

Manufacturer / TM Owner

Baxter B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mannitol is used as an osmotic agent to manage conditions where fluid shifts reduce pressure or promote diuresis.

  • Intracranial hypertension: lowers intracranial pressure by drawing fluid from brain tissue into the vascular compartment.
  • Intraocular hypertension: reduces intraocular pressure in acute glaucoma or ocular surgery.
  • Acute renal failure: promotes diuresis to facilitate renal clearance of waste products.

How It Works

  • Mannitol acts as an osmotically active solute that remains largely extracellular. After intravenous infusion, it raises plasma osmolarity, creating an osmotic gradient that pulls water from intracellular and interstitial spaces into the intravascular compartment. The resulting plasma expansion increases renal glomerular filtration and urine output, while also decreasing cerebral and ocular tissue volume and improving overall fluid balance.

Side Effects

Mannitol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nausea or vomiting: gastrointestinal upset after infusion.
  • Electrolyte disturbances: hyponatremia or hypernatremia.
  • Transient hypotension: due to rapid plasma expansion.

Serious or Rare Side Effects

  • Anaphylactic reaction: severe allergy requiring immediate treatment.
  • Hemolysis: especially in patients with G6PD deficiency.
  • Pulmonary edema: fluid overload in susceptible patients.
  • Severe electrolyte imbalance: may cause cardiac arrhythmias.

Precautions & Warnings

When using Mannitol, clinicians should observe several safety measures to minimise risks.

  • Monitor fluid balance: assess input and output closely during therapy.
  • Check serum electrolytes: especially sodium and potassium levels before and during treatment.
  • Use caution in heart failure: risk of pulmonary edema from fluid shifts.
  • Adjust infusion rate in renal impairment: slower administration may be required.
  • Avoid rapid bolus in patients with intracranial lesions: may cause sudden pressure changes.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Mannitol can alter the pharmacodynamics or pharmacokinetics of several drugs, necessitating careful review.

Major Interactions (Avoid)

  • Loop diuretics: additive diuretic effect may cause severe dehydration.
  • Insulin: hyperosmolar state can impair glucose control, increasing insulin requirements.
  • ACE inhibitors or ARBs: combined effect may precipitate hypotension.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may reduce renal prostaglandin synthesis, diminishing Mannitol‑induced diuresis.
  • Aminoglycoside antibiotics: heightened risk of nephrotoxicity.
  • Anticoagulants: volume expansion may affect coagulation parameters.

Frequently Asked Questions

Mannitol Baxter is an intravenous osmotic diuretic indicated for lowering elevated intracranial pressure, reducing intraocular pressure in acute eye conditions, and promoting diuresis in patients with acute renal failure to aid waste elimination.

Mannitol increases plasma osmolarity after IV infusion, creating an osmotic gradient that draws water from cells and interstitial spaces into the bloodstream. This expands plasma volume, enhances glomerular filtration, and reduces tissue swelling in the brain and eye.

The prescribed dose of Mannitol is individualized by the treating clinician based on the specific indication, patient weight, renal function, and desired therapeutic effect. No fixed regimen is provided here; the prescriber sets the appropriate infusion rate and total amount.

Safety data for Mannitol in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Mannitol Baxter product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mannitol is a non‑ionic, high‑molecular‑weight sugar alcohol that provides rapid plasma expansion, whereas agents like hypertonic saline contain ions and may have different electrolyte effects. Mannitol’s renal clearance and osmotic potency make it a preferred choice for acute pressure reduction and diuresis in many clinical protocols.

Mannitol Baxter should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vials in their original packaging until use to maintain sterility and stability.

Mannitol is given by intravenous infusion. The solution is typically diluted with compatible IV fluids and administered over a controlled period, with the infusion rate adjusted by the healthcare professional according to the clinical response and patient tolerance.

Serious risks include anaphylactic reactions, hemolysis (especially in G6PD‑deficient patients), pulmonary edema from fluid overload, and severe electrolyte disturbances that can lead to cardiac arrhythmias. Prompt recognition and management of these events are essential.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial bleeding, uncontrolled heart failure, or severe pulmonary edema. Caution is also advised in individuals with renal impairment or electrolyte imbalances.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.